| P2093 | author name string | Alexander Drilon | |
| | Jarushka Naidoo | |
| P2860 | cites work | The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants | Q24317051 |
| | The structural basis of the activation of Ras by Sos | Q24320225 |
| | Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers | Q24611043 |
| | A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene | Q24647664 |
| | The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis | Q24650902 |
| | Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy | Q27313799 |
| | Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy | Q27824765 |
| | Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma | Q27851448 |
| | Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers | Q27851457 |
| | A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations | Q27851664 |
| | A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response | Q27851728 |
| | Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study | Q27851971 |
| | KRAS mutations in non-small cell lung cancer | Q28240568 |
| | RAS oncogenes: weaving a tumorigenic web | Q28250360 |
| | Prognostic value ofTP53,KRASandEGFRmutations in nonsmall cell lung cancer: the EUELC cohort | Q57419582 |
| | Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype | Q61899364 |
| | K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung | Q68532141 |
| | Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient | Q71265374 |
| | Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer | Q74611887 |
| | Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer | Q79317427 |
| | Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models | Q80352305 |
| | Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers | Q81001986 |
| | Comprehensive genomic characterization of squamous cell lung cancers | Q28274701 |
| | Ras oncogenes: split personalities | Q29615405 |
| | Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 | Q29617043 |
| | Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial | Q33521023 |
| | Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. | Q33561943 |
| | Spectrum of LKB1, EGFR, and KRAS mutations in chinese lung adenocarcinomas | Q33563803 |
| | Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications | Q33899708 |
| | Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study | Q33969308 |
| | C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. | Q34124421 |
| | Lung adenocarcinoma of never smokers and smokers harbor differential regions of genetic alteration and exhibit different levels of genomic instability | Q34193618 |
| | The role of proteasome inhibition in nonsmall cell lung cancer | Q35001441 |
| | Development of farnesyl transferase inhibitors: a review | Q36263983 |
| | RHOA-FAK is a required signaling axis for the maintenance of KRAS-driven lung adenocarcinomas | Q36763119 |
| | KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma | Q37067360 |
| | The potential role of mTOR inhibitors in non-small cell lung cancer | Q37096395 |
| | Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer | Q37274280 |
| | Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma | Q37428076 |
| | Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy | Q38048579 |
| | KRAS mutations in lung cancer | Q38057476 |
| | Response and resistance to NF-κB inhibitors in mouse models of lung adenocarcinoma | Q38256553 |
| | Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. | Q38409218 |
| | KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer | Q38432430 |
| | KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies | Q39213209 |
| | Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib | Q39271324 |
| | GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition | Q39606314 |
| | A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras | Q39991720 |
| | AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl | Q40093939 |
| | Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer | Q40591213 |
| | A Phase II, Open-Label, Randomized Study to Assess the Efficacy and Safety of AZD6244 (ARRY-142886) Versus Pemetrexed in Patients with Non-small Cell Lung Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens | Q42673662 |
| | Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer | Q43184359 |
| | A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutation | Q44242530 |
| | Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer | Q44425380 |
| | Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells. | Q45917382 |
| | Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study | Q46213605 |
| | Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. | Q46484712 |
| | Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib | Q46618741 |
| | Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer | Q46892013 |
| | Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer | Q47992122 |
| | New therapeutic strategies in the second line setting of advanced or metastatic pancreatic adenocarcinoma | Q48021940 |
| | Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers. | Q54771804 |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 155-178 | |
| P577 | publication date | 2016-01-01 | |
| P1433 | published in | Advances in Experimental Medicine and Biology | Q4686385 |
| P1476 | title | KRAS-Mutant Lung Cancers in the Era of Targeted Therapy | |
| P478 | volume | 893 | |